REL and thyroid gland papillary carcinoma: Overexpression of METTL3 in cancer cells can destabilize CD70 mRNA in a YTHDF2‐dependent manner, thereby improving the efficacy of anti‐PD‐1 therapy in thyroid cancer.[44] Moreover, METTL3 inhibited the progression of papillary thyroid cancer through m6A/c‐Rel/IL‐8‐mediated neutrophil infiltration.[45] Nevertheless, no studies have shed light on the function or mechanism of METTL3‐mediated m6A methylation in thyroid carcinoma differentiation.